Update says a strong Q4, continuing into FY23
In a Trading Update Benchmark Holdings reports a strong fourth quarter with trading better than expected across each of its three business areas. Consequently – subject to audit – the Group expects (adj.) EBITDA, for the year to 30 September, to be in the range of £30.0m - £31.0m, i.e. up to 14% above of our estimate of £27.3m.The Genetics business area closed the year ahead of management expectations due to strong Q4 demand for salmon eggs; Advanced Nutrition delivered revenue ahead of plan across all business segments; and in Health they noted increased activity and revenues from proprietary Ectosan® Vet and Clean Treat® (CT) treatment for sea lice in farmed salmon ahead of the primary sea lice season.
The Group continues with its plan to list on the Euronext Growth Oslo by the end of calendar 2022 and list on the Oslo Børs in the first half of calendar year 2023, subject to market conditions. In the light of this positive update, we shall review financial estimates when more detail is released.
Our fair value for Benchmark is 63p/share.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.